Other diagnostic features suggestive of POI are low levels of anti-Mullerian hormone (AMH) level and circulating estrogen 1, 2, 3. POI is diagnosed based on serum follicle-stimulating hormone (FSH) levels in the menopausal range and secondary amenorrhea. Amenorrhea, infertility, and sigs of estrogen insufficiency are the main clinical manifestations reported in affected individuals.
Primary ovarian insufficiency (POI), previously known as premature ovarian failure, is characterized by the loss of ovarian function before 40 years of age. Our findings indicate that the hMSC secretome may be a novel treatment approach for restoring granulosa cell and ovarian function in patients with POI. Our data suggest that hMSC CM stimulates granulosa cell proliferation and function, which may explain the therapeutic effect of hMSCs in our chemotherapy-induced POI animal model. We also demonstrated that the expression of steroidogenic enzymes involved in the production of estrogen, CYP19A1 and StAR, are significantly elevated in hMSC CM-treated HGrC1 cells. We showed by FACS analysis that treatment of HGrC1 cells with hMSC-conditioned media (hMSC CM) stimulates cellular proliferation. Here, we report that the hMSC secretome increased the proliferation of human granulosa cells (HGrC1). However, the regenerative mechanism underlying the hMSC effect in POI mice is not fully understood. Our recently published studies demonstrated that intraovarian transplantation of human mesenchymal stem cells (hMSCs) can restore fertility in a chemotherapy-induced POI mouse model. Gonadotoxic chemotherapy reagents damage granulosa cells, which are essential for follicular function and development. POI is frequently induced by chemotherapy. It clinically manifests as amenorrhea, infertility, and signs of estrogen insufficiency. Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world.Primary ovarian insufficiency (POI) is defined as the loss of ovarian function before 40 years of age. Combining intelligently implemented technologies with in-depth industry applications knowledge and support, Malvern provides customers with the competitive advantage they demand. Complementary materials characterization systems deliver inter-related measurements that reflect the complexities of particulates and disperse systems, nanomaterials and macromolecules. Malvern’s measurement solutions for scientists, technologists and engineers advance continually through customer collaboration. Malvern delivers the systems, support and expertise that ensure the analytical integrity and productivity needed to drive research, development and manufacturing. These include particle size, particle shape, zeta potential, molecular weight, size and conformation, rheological properties and chemical identification.
Malvern Instruments is a market leader in measuring performance controlling material properties. Malvern, Malvern Instruments and Zetasizer are registered trademarks of Malvern Instruments Ltd To contact a member of the Malvern team email. While these new details will help users in assessing whether a given instrument in the Zetasizer family will suit particular application requirements, Malvern experts are always available to provide additional information, guidance and support. The new specifications document details the limits of performance for each instrument in the range, including the Zetasizer Nano ZS, S90 and ZS90, as well as the Zetasizer APS and Zetasizer µV. Zetasizer particle characterization systemsįull updated specification details are available online at, with all supporting documentation freely downloadable.